IRWD Valuation

Ironwood Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

0.816

-0.003(-0.366%)1D

Overview
Forecast
Valuation
Earnings

IRWD Relative Valuation

IRWD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, IRWD is overvalued; if below, it's undervalued.

Historical Valuation

Ironwood Pharmaceuticals Inc (IRWD) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.48 is considered Undervalued compared with the five-year average of 14.79. The fair price of Ironwood Pharmaceuticals Inc (IRWD) is between 13.90 to 17.60 according to relative valuation methord. Compared to the current price of 0.82 USD , Ironwood Pharmaceuticals Inc is Undervalued By 94.13%.

Relative Value

Fair Zone

13.90-17.60

Current Price：0.82

94.13%

Undervalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

-0.40

P/B

Median3y

-1.19

Median5y

15.73

59.12

FCF Yield

Median3y

21.41

Median5y

17.30

Competitors Valuation Multiple

The average P/S ratio for IRWD's competitors is 27.77, providing a benchmark for relative valuation. Ironwood Pharmaceuticals Inc Corp (IRWD) exhibits a P/S ratio of 0.48, which is -98.28% above the industry average. Given its robust revenue growth of -45.05%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

IRWD.O

Ironwood Pharmaceuticals Inc

0.48

Average P/S: 27.77

-45.05%